Replies to post #4560 on Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

The way I see the endpoint topic is that it is far easier to achieve a PFS endpoint than an OS endpoint, so it does improve our chances considerably. But that has been a "known known" for months now.
A 9% drop on Keytruda makes no sense at all, since it is clearly not a PEGph20 issue and that trial has a long way to go before it impacts us in any way.
-Fritz